HDAC11 deficiency improves muscle phenotype in a Duchenne muscular dystrophy murine model by reducing inflammation and fibrosis


Por: Odria, R, Mercado-Amarilla, A, Soler-Botija, C, Borràs, DM, Ohana, J, Maestre-Mora, P, Bigot, A, Suárez-Calvet, X, Gallardo, E, Nogales-Gadea, G and Suelves, M

Publicada: 1 feb 2026 Ahead of Print: 1 dic 2025
Resumen:
Duchenne muscular dystrophy (DMD) is a devastating genetic disorder caused by mutations in the dystrophin gene, which encodes for an essential protein to maintain muscle integrity. Loss of dystrophin leads to progressive muscle degeneration, chronic inflammation and replacement of muscle by fibroadipose tissue. To date there is no cure for DMD and the identification of novel molecular targets involved in disease progression is needed to design new therapies to slow DMD progression and prolong survival. Here, we show for the first time that genetic deficiency of HDAC11 in a mouse model of DMD has a positive impact in dystrophic phenotype by reducing muscle damage and fibrosis, which results in improved muscle function. In addition, HDAC11-/- dystrophic muscles show diminished inflammation and changes in the inflammatory environment that positively affect regeneration. Importantly, a partial reduction in HDAC11 levels also improved the dystrophic phenotype, and this therapeutic impact was also observed in old mice. Dystrophic FAPs deficient for HDAC11 underwent more apoptosis, limiting their expansion, and produced less collagen. Single cell RNA sequencing data identified distinct FAP subpopulations, which differ between genotypes. These results were in agreement with the reduced inflammation observed in dKO mice, and suggest changes in the FAPs plasticity. Overall, our results show unequivocally that the total or partial reduction of HDAC11 levels improves the dystrophic phenotype, both histologically and functionally, in young and old mice, therefore HDAC11 could be envisioned as a new potential therapeutic target to ameliorate DMD pathology.

Filiaciones:
:
 Inst Invest Ciencies Salut Germans Trias i Pujol I, Grup Recerca Malaties Neuromusculars Badalona GREN, Badalona 08916, Spain

 Univ Barcelona, Doctoral Program Biomed, Barcelona, Spain

Mercado-Amarilla, A:
 Inst Invest Ciencies Salut Germans Trias i Pujol I, Grup Recerca Malaties Neuromusculars Badalona GREN, Badalona 08916, Spain

Soler-Botija, C:
 IGTP, ICREC Heart Failure & Cardiac Regenerat Res Progra, Badalona, Spain

 Inst Salud Carlos III, CIBER Cardiovasc Dis CIBERCV, Madrid, Spain

:
 Inst Invest Ciencies Salut Germans Trias i Pujol I, Grup Recerca Malaties Neuromusculars Badalona GREN, Badalona 08916, Spain

Ohana, J:
 Sorbonne Univ, Inst Myol, Ctr Rech Myol, INSERM, Paris, France

Maestre-Mora, P:
 Inst Invest Ciencies Salut Germans Trias i Pujol I, Grup Recerca Malaties Neuromusculars Badalona GREN, Badalona 08916, Spain

Bigot, A:
 Sorbonne Univ, Inst Myol, Ctr Rech Myol, INSERM, Paris, France

Suárez-Calvet, X:
 Inst Invest St Pau, Lab Malalties Neuromusculars, Barcelona, Spain

 Inst Salud Carlos III, Rare Dis Network Res Ctr, CIBERER U762, Madrid, Spain

Gallardo, E:
 Inst Invest St Pau, Lab Malalties Neuromusculars, Barcelona, Spain

 Inst Salud Carlos III, Rare Dis Network Res Ctr, CIBERER U762, Madrid, Spain

:
 Inst Invest Ciencies Salut Germans Trias i Pujol I, Grup Recerca Malaties Neuromusculars Badalona GREN, Badalona 08916, Spain

:
 Inst Invest Ciencies Salut Germans Trias i Pujol I, Grup Recerca Malaties Neuromusculars Badalona GREN, Badalona 08916, Spain
ISSN: 00243205





Life Sciences
Editorial
Elsevier BV, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND, Países Bajos
Tipo de documento: Article
Volumen: 386 Número:
Páginas: 124150-124150
WOS Id: 001655980500001
ID de PubMed: 41407152

MÉTRICAS